The former head of the Strategic National Stockpile said the federal government can’t efficiently manage the medical product inventory in the stockpile because there isn’t enough transparency in the supply chain, and he urged Congress to step in. Lawmakers should give stockpile managers authority to access FDA data on drug products and their manufacturers, and require drug makers to share more information on the origins of active pharmaceutical ingredients used in their finished products, Greg Burel, former director of the...